Recombinant Anti-CD55 x Anti-HLA-A Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD55 antibody variable domain is fused to the C terminal of an IgG of anti-HLA-A antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can recruit complements to tumor cells. It is designed for the research of Renal cell cancer (RCC); Solid tumors therapy.